Daraxonrasib doubles pancreatic-cancer survival

Revolution Medicines' pan-RAS inhibitor daraxonrasib nearly doubled overall survival in metastatic pancreatic adenocarcinoma: 13.2 months combined versus 6.7 months chemotherapy alone in phase 3. FDA granted fast-track and expanded-access approval. Analysts view this as the inflection point for the first RAS inhibitor to reshape treatment standards.